Loading…
Cognition Therapeutics Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -92.3% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $1.35 | $0.70 | $1.85 | $2.10 | $6.32 | |
| P/B | 2.8x | 3.5x | 2.3x | 2.9x | 1.5x | 2.8x |
| EPS | -$0.32 | -$0.86 | -$0.86 | -$0.91 | -$3.13 | |
| ROE | -68.53% | -68.53% | -181.18% | -105.37% | -53.16% | -22.85% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| VRCAVerrica Pharmaceuticals Inc. | $5.69 | — | 22.7x | — | — | $97.75M |
| KLRSKalaris Therapeutics, Inc. | $4.03 | — | 1.7x | — | -79.91% | $95.93M |
| YARWYarrow Bioscience, Inc. | $37.00 | — | — | — | — | $98.78M |
| DHDefinitive Healthcare Corp. | $0.89 |
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
Company description provided by Yahoo Finance.
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.7x |
| — |
| -78.37% |
| $95M |
| PARKPark Dental Partners, Inc. | $20.85 | — | 3.3x | — | -24.16% | $99.15M |
| PTHSPelthos Therapeutics Inc. | $24.73 | — | — | — | — | $94.68M |